

ASX Announcement

18 May 2022



Updated COVID-19 RAT receives Regulatory Approval in Europe

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to advise that it has successfully registered an updated EuGeni COVID-19 Rapid Antigen Test (RAT)¹ in Europe under the In Vitro Diagnostic Directive (IVDD) 98/79/EC Regulations. The new registration strengthens the EuGeni COVID-19 RAT's competitive position as it broadens and aligns sampling methods to current trends in standard of care for the European market. The updated test will provide additional leverage as AnteoTech expands the EuGeni COVID-19 RAT footprint in Europe.

The new registration is for the same core SARS-CoV-2 Ag Rapid Diagnostic Test registered in April 2021 but now covers multiple use claims (sampling methods) to include combined nose and throat sampling and nasal mid-turbinate sampling on top of the original nasopharyngeal sampling method.

To establish the new use claims, AnteoTech completed analytical and clinical performance evaluations in the US and the UK respectively, that focussed on validating the test's effectiveness in detecting the Omicron variant of SARS-CoV-2, the dominant variant currently circulating globally. This work will be used in future regulatory submissions.

The European Clinical Trial currently underway is also evaluating the updated multiple-use claim, to enable this to be included in the EU Common List registration application. As AnteoTech receives orders for the updated multiple-use claim test kits, the original nasopharyngeal test will be phased out.

ENDS

This announcement has been authorised for release by Mr Derek Thomson, Chief Executive Officer.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

¹ The AnteoTech Antigen Rapid Test detects the SARS-CoV-2 virus that causes the disease called COVID-19

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.

Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Latest News** bulletin, our email alert service.

For personal use only